Ambeed.cn

首页 / / / / Resibufogenin

酯蟾毒配基 /Resibufogenin {[allProObj[0].p_purity_real_show]}

货号:A151203 同义名: 蟾力苏 / Bufogenin;Recibufogenin

Resibufogenin, a natural product isolated and purified from the glandular body of Bufo bufo gargarizans Cantor, displays great potential as a chemotherapeutic agent in oncology.

Resibufogenin 化学结构 CAS号:465-39-4
Resibufogenin 化学结构
CAS号:465-39-4
Resibufogenin 3D分子结构
CAS号:465-39-4
Resibufogenin 化学结构 CAS号:465-39-4
Resibufogenin 3D分子结构 CAS号:465-39-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Resibufogenin 纯度/质量文件 产品仅供科研

货号:A151203 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell, 2024, 101755. Ambeed. [ A399663 ]
EMBO J., 2024. Ambeed. [ A295334 ]
JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]
JMC, 2024. Ambeed. [ A210558 , A1518164 ]
Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]
更多 >
产品名称 Bax Bcl-2 Bcl-B Bcl-w Bcl-xL Bfl-1 Mcl-1 其他靶点 纯度
BTSA1 99%+
HA14-1 +

Bcl-2, IC50: 9 μM

98%
Venetoclax ++++

Bcl-2, Ki: <0.01 nM

99%
Navitoclax 99%+
Obatoclax Mesylate +++

Bcl-2, Ki: 0.22 μM

98%
ABT-737 +++

Bcl-2, EC50: 30.3 nM

+

Bcl-B, EC50: 1.82 μM

+++

Bcl-w, EC50: 197.8 nM

+++

Bcl-xL, EC50: 78.7 nM

99%+
Gambogic Acid +

Bcl-2, IC50: 1.21 μM

Bfl-1, IC50: 1.06 μM

++

Bcl-B, IC50: 0.66 μM

++++

Bcl-w, IC50: 0.02 μM

+

Bcl-xL, IC50: 1.47 μM

+

Bfl-1, IC50: 1.06 μM

++

Mcl-1, IC50: 0.79 μM

Caspase 99% HPLC
BH3I-1 +

BH3-Bcl-xL interaction, Ki: 2.4 μM

98%
A-1331852 ++++

Bcl-xL, Ki: <0.01 nM

99%+
A-1210477 ++++

MCL-1, IC50: 26.2 nM

99%+
Maritoclax 97%
TW-37 +++

Bcl-2, Ki: 0.29 μM

+

Bcl-xL, Ki: 1.11 μM

+++

Mcl-1, Ki: 0.26 μM

98%
UMI-77 ++

Mcl-1, Ki: 490 nM

97%
(R)-(-)-Gossypol acetic acid ++

Bcl-2, Ki: 0.32 μM

++

Bcl-xL, Ki: 0.48 μM

+++

Mcl-1, Ki: 0.18 μM

98%
Sabutoclax ++

Bcl-2, IC50: 0.32 μM

Bfl-1, IC50: 0.62 μM

++

Bcl-xL, IC50: 0.31 μM

++

Bfl-1, IC50: 0.62 μM

+++

Mcl-1, IC50: 0.20 μM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Capase-7 Caspase Caspase-1 Caspase-10 Caspase-2 Caspase-3 Caspase-4 Caspase-5 Caspase-6 Caspase-8 Caspase-9 其他靶点 纯度
Emricasan 99%+
Z-VAD(OMe)-FMK 99%+
Z-VAD-FMK 99%+
Q-VD-OPh 97%
VX-765 ++++

Caspase-1, Ki: 0.8 nM

++++

Caspase-4, Ki: <0.6 nM

99%+
Ac-DEVD-CHO +++

caspase-7, Ki: 1.6 nM

+++

Caspase-1, Ki: 18 nM

+++

caspase-10, Ki: 12 nM

+

caspase-2, Ki: 1.71 μM

++++

Caspase-3, Ki: 230 pM

++

Caspase-4, Ki: 132 nM

++

caspase-5, Ki: 205 nM

+++

caspase-6, Ki: 31 nM

++++

caspase-8, Ki: 0.92 nM

++

Caspase-9, Ki: 60 nM

98%+
Z-DEVD-FMK 98%
Z-IETD-FMK 98%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Cdc CDK1 CDK19 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CLK 其他靶点 纯度
XL413 hydrochloride ++++

Cdc7, IC50: 3.4 nM

99%+
SU9516 +++

CDK1, IC50: 40 nM

+++

CDK2, IC50: 22 nM

++

CDK4, IC50: 200 nM

99%+
RO-3306 +++

CDK1, Ki: 20 nM

ERK,SGK 98%
R547 ++++

CDK1/CyclinB, Ki: 2 nM

++++

CDK2/CyclinE, Ki: 3 nM

++++

CDK4/CyclinD1, Ki: 1 nM

99%+
BMS-265246 ++++

CDK1/CyclinB, IC50: 6 nM

++++

CDK2/CyclinE, IC50: 9 nM

+

CDK4/CyclinD, IC50: 230 nM

99%+
NU6027 +

CDK1, Ki: 2.5 μM

+

CDK2, Ki: 1.3 μM

DNA-PK 98%
Purvalanol A ++++

Cdc2/CyclinB, IC50: 4 nM

+++

CDK2/CyclinE, IC50: 35 nM

CDK2/CyclinA, IC50: 70 nM

+

CDK4/CyclinD1, IC50: 850 nM

99%+
SCH900776 ++

CDK2, IC50: 0.16 μM

99%+
AUZ 454 ++++

CDK2(C118L), Kd: 18.6 nM

CDK2(A144C), Kd: 9.7 nM

99%+
A-674563 HCl ++

CDK2, Ki: 46 nM

PKA 98%
JNJ-7706621 ++++

CDK1/CyclinB, IC50: 9 nM

++++

CDK2/CyclinE, IC50: 3 nM

CDK2/CyclinA, IC50: 4 nM

++

CDK3/CyclinE, IC50: 58 nM

+

CDK4/CyclinD1, IC50: 253 nM

++

CDK6/CyclinD1, IC50: 175 nM

99%+
AT7519 ++

CDK1/CyclinB, IC50: 210 nM

++

CDK2/CyclinA, IC50: 47 nM

+

CDK3/CyclinE, IC50: 360 nM

++

CDK4/CyclinD1, IC50: 100 nM

+++

CDK5/p35, IC50: 13 nM

++

CDK6/CyclinD3, IC50: 170 nM

++++

CDK9/CyclinT, IC50: <10 nM

98+%
PHA-793887 ++

CDK1/CyclinB, IC50: 60 nM

++++

CDK2/CyclinE, IC50: 8 nM

CDK2/CyclinA, IC50: 8 nM

++

CDK4/CyclinD1, IC50: 62 nM

++++

CDK5/p25, IC50: 5 nM

++++

CDK7/CyclinH, IC50: 10 nM

++

CDK9/CyclinT1, IC50: 138 nM

99%+
Milciclib +

CDK1/CyclinB, IC50: 398 nM

++

CDK2/CyclinE, IC50: 363 nM

CDK2/CyclinA, IC50: 45 nM

++

CDK4/CyclinD1, IC50: 160 nM

+

CDK5/p35, IC50: 265 nM

++

CDK7/CyclinH, IC50: 150 nM

99%+
Kenpaullone +

CDK1/CyclinB, IC50: 0.4μM

+

CDK2/CyclinE, IC50: 7.5μM

CDK2/CyclinA, IC50: 0.68μM

+

CDK5/p35, IC50: 0.85μM

98%
SNS-032 +++

CDK2/CyclinE, IC50: 48 nM

CDK2/CyclinA, IC50: 38 nM

+

CDK5/p35, IC50: 340 nM

++

CDK7/CyclinH, IC50: 62 nM

++++

CDK9/CyclinT, IC50: 4 nM

99%+
Dinaciclib ++++

CDK1, IC50: 3 nM

++++

CDK2, IC50: 1 nM

++++

CDK5, IC50: 1 nM

++++

CDK9, IC50: 4 nM

99%+
PHA-767491 hydrochloride ++++

Cdc7, IC50: 10 nM

+

CDK1, IC50: 250 nM

+

CDK2, IC50: 240 nM

+

CDK5, IC50: 460 nM

+++

CDK9, IC50: 34 nM

MK2 98%
(R)-Roscovitine +

Cdc2/CyclinB, IC50: 0.65 μM

+

CDK2/CyclinE, IC50: 0.7 μM

CDK2/CyclinA, IC50: 0.7 μM

++

CDK5/p35, IC50: 0.16 μM

99%+
Narazaciclib ++++

CDK4/CyclinD1, IC50: 3.87 nM

++++

CDK6/CyclinD1, IC50: 9.82 nM

RET 99%+
Palbociclib ++++

CDK4/CyclinD1, IC50: 11 nM

CDK4/CyclinD3, IC50: 9 nM

+++

CDK6/CyclinD2, IC50: 15 nM

99%
Abemaciclib ++++

CDK4, IC50: 2 nM

++++

CDK6, IC50: 10 nM

99%
Ribociclib ++++

CDK4, IC50: 10 nM

+++

CDK6, IC50: 39 nM

98%
Palbociclib isethionate ++++

CDK4/CyclinD1, IC50: 11 nM

CDK4/CyclinD3, IC50: 9 nM

+++

CDK6/CyclinD2, IC50: 15 nM

99%+
BS-181 HCl +++

CDK7, IC50: 21 nM

99%+
(E/Z)-THZ1 dihydrochloride ++++

CDK7, IC50: 3.2 nM

99%+
LDC4297 ++++

CDK7, IC50: 0.13 nM

99%+
Senexin A +

CDK19, Kd: 0.31 μM

+

CDK8, Kd: 0.83 μM

98+%
MSC2530818 ++++

CDK8, IC50: 2.6 nM

99%+
Wogonin 99%+
Riviciclib HCl ++

CDK1/CyclinB, IC50: 79 nM

+

CDK2/CyclinE, IC50: 2.54 μM

CDK2/CyclinA, IC50: 224 nM

++

CDK4/CyclinD1, IC50: 63 nM

+

CDK6/CyclinD3, IC50: 396 nM

+

CDK7/CyclinH, IC50: 2.87 μM

+++

CDK9/CyclinT1, IC50: 20 nM

99+%
LDC000067 +

CDK2, IC50: 2.441 μM

++

CDK9, IC50: 44 nM

98%
Flavopiridol +++

CDK1, IC50: 40 nM

+++

CDK2, IC50: 40 nM

+++

CDK4, IC50: 40 nM

+++

CDK6, IC50: 40 nM

+

CDK7, IC50: 300 nM

+++

CDK9, IC50: 20 nM

99%+
LY2857785 +

CDK7, IC50: 0.246 μM

+++

CDK8, IC50: 0.016 μM

+++

CDK9, IC50: 0.011 μM

99%+
AZD-5438 +++

CDK1, IC50: 16 nM

++++

CDK2, IC50: 6 nM

+++

CDK9, IC50: 20 nM

99%+
ML167 ++

Dyrk1B , IC50: 1648 nM

CLK4, IC50: 136 nM

99%+
(E/Z)-TG003 +++

mCLK1, IC50: 200 nM

mCLK4, IC50: 15 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Akt Akt1 Akt2 Akt3 其他靶点 纯度
Honokiol MEK 98%
PF-04691502 ++++

P-Akt (S473), IC50: 3.8 nM

P-Akt (T308), IC50: 7.5 nM

98+%
PHT-427 +

Akt, Ki: 2.7 μM

99%+
Deguelin PI3K 99%+
TIC10 isomer ERK 98+%
Perifosine +

Akt, IC50: 4.7 μM

98%
Miltefosine PI3K,PKC 98%
Triciribine +

Akt, IC50: 130 nM

99%+
Uprosertib +

Akt1, IC50: 180 nM

+

Akt2, IC50: 328 nM

++

Akt3, IC50: 38 nM

99%+
Afuresertib ++++

Akt1, Ki: 0.08 nM

++++

Akt2, Ki: 2 nM

++++

Akt3, Ki: 2.6 nM

99%+
Miransertib ++++

Akt1, IC50: 5 nM

++++

Akt2, IC50: 4.5 nM

++

Akt3, IC50: 16 nM

98+%
GSK-690693 ++++

Akt1, IC50: 2 nM

+++

Akt2, IC50: 13 nM

+++

Akt3, IC50: 9 nM

99%+
AT7867 ++

Akt1, IC50: 32 nM

++

Akt2, IC50: 17 nM

++

Akt3, IC50: 47 nM

PKA 99%+
AKT inhibitor VIII ++

Akt1, IC50: 58 nM

+

Akt2, IC50: 210 nM

+

Akt3, IC50: 2119 nM

98+%
MK-2206 2HCl +++

Akt1, IC50: 8 nM

+++

Akt2, IC50: 12 nM

+

Akt3, IC50: 65 nM

99%+
Ipatasertib ++++

Akt1, IC50: 5 nM

++

Akt2, IC50: 18 nM

+++

Akt3, IC50: 8 nM

99%+
AT13148 ++

Akt1, IC50: 38 nM

+

Akt2, IC50: 402 nM

++

Akt3, IC50: 50 nM

PKA 98+%
Capivasertib ++++

Akt1, IC50: 3 nM

+++

Akt2, IC50: 8 nM

+++

Akt3, IC50: 8 nM

99%+
A-674563 HCl +++

Akt1, Ki: 11 nM

PKA 98%
CCT128930 +++

Akt2, IC50: 6 nM

PKA 98+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 GSK-3 GSK-3α GSK-3β 其他靶点 纯度
AZD2858 +

GSK-3, IC50: 68 nM

98+%
Bikinin 99%+
GSK 3 Inhibitor IX ++++

GSK-3, IC50: 5 nM

99%+
AZD1080 +++

GSK-3α, IC50: 6.9 nM

++

GSK-3β, IC50: 31 nM

99%+
BIO-acetoxime +++

GSK-3α, IC50: 10 nM

+++

GSK-3β, IC50: 10 nM

95%
SB-216763 ++

GSK-3α, IC50: 34.3 nM

++

GSK-3β, IC50: ~34.3 nM

98%
SB 415286 +

GSK-3α, IC50: 78 nM

+

GSK-3β, IC50: ~78 nM

99%+
CHIR-98014 ++++

GSK-3α, IC50: 0.65 nM

++++

GSK-3β, IC50: 0.58 nM

98%
LY2090314 ++++

GSK-3α, IC50: 1.5 nM

++++

GSK-3β, IC50: 0.9 nM

99%+
CHIR 99021 +++

GSK-3α, IC50: 10 nM

++++

GSK-3β, IC50: 6.7 nM

99%+
TDZD-8 +

GSK-3β, IC50: 2 μM

99%+
Indirubin +

GSK-3β, IC50: 0.6 μM

98%
IM-12 ++

GSK-3β, IC50: 53 nM

98%
TWS119 ++

GSK-3β, IC50: 30 nM

98%
1-Azakenpaullone +++

GSK-3β, IC50: 18 nM

99%+
AR-A014418 ++

GSK-3β, Ki: 38 nM

99%+
Tideglusib +

GSK-3β, IC50: 60 nM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 C2β p110α p110β p110γ p110δ PI3K Vps34 其他靶点 纯度
A66 +

C2β, IC50: 462 nM

++

p110α, IC50: 32 nM

99%+
Taselisib +

C2β, IC50: 292 nM

++++

PI3Kα, Ki: 0.29 nM

+++

PI3Kβ, Ki: 9.1 nM

++++

PI3Kγ, Ki: 0.97 nM

++++

PI3Kδ, Ki: 0.12 nM

+

hVps34, IC50: 374 nM

99%+
Gedatolisib ++++

PI3Kα, IC50: 0.4 nM

+++

PI3Kγ, IC50: 5.4 nM

mTOR 98%
HS-173 ++++

PI3Kα , IC50: 0.8 nM

99%+
Serabelisib +++

PI3Kα, IC50: 21 nM

99%+
GNE-477 ++++

PI3Kα, IC50: 4 nM

mTOR 98%
YM-201636 +

p110α, IC50: 3.3 μM

PIKfyve 98%
AS-252424 +

PI3Kα, IC50: 935 nM

++

PI3Kγ, IC50: 33 nM

99%
Alpelisib +++

PI3Kα, IC50: 5 nM

99%+
AS-604850 +

PI3Kα, IC50: 4.5 μM

+

PI3Kγ, IC50: 0.25 μM

98+%
SF2523 ++

PI3Kα, IC50: 34 nM

++

PI3Kγ, IC50: 158 nM

mTOR,DNA-PK 99%+
Inavolisib ++++

PI3K alpha, IC50: 0.038 nM

99%+
Bimiralisib ++++

PI3Kα, Kd: 1.5 nM

+++

PI3Kβ, Kd: 11 nM

++

PI3Kγ, Kd: 25 nM

++

PI3Kδ, Kd: 25 nM

mTOR 99%+
GSK1059615 ++++

PI3Kα, IC50: 0.4 nM

++++

PI3Kβ, IC50: 0.6 nM

+++

PI3Kγ, IC50: 5 nM

++++

PI3Kδ, IC50: 2 nM

mTOR 98%
GSK2636771 98%
Fimepinostat +++

PI3Kα, IC50: 19 nM

++

PI3Kβ, IC50: 54 nM

++

PI3Kδ, IC50: 39 nM

99%+
VS-5584 ++++

PI3Kα, IC50: 2.6 nM

+++

PI3Kβ, IC50: 21 nM

++++

PI3Kγ, IC50: 3.0 nM

++++

PI3Kδ, IC50: 2.7 nM

mTOR 99%
Dactolisib ++++

p110α1, IC50: 4 nM

++

p110β, IC50: 75 nM

+++

p110γ, IC50: 5 nM

+++

p110δ, IC50: 7 nM

98+%
PI-103 ++++

p110α, IC50: 2 nM

++++

p110β, IC50: 3 nM

+++

p110γ, IC50: 15 nM

++++

p110δ, IC50: 3 nM

mTOR,DNA-PK 99%+
PI-3065 +

p110β, IC50: 1078 nM

+++

p110δ, IC50: 15 nM

99%+
Voxtalisib ++

PI3Kα, IC50: 39 nM

++

PI3Kβ, IC50: 113 nM

+++

PI3Kγ, IC50: 9 nM

++

PI3Kδ, IC50: 43 nM

mTOR,DNA-PK 99%+
AZD-8835 +++

PI3Kα, IC50: 6.2 nM

+

PI3Kβ, IC50: 431 nM

++

PI3Kγ, IC50: 90 nM

+++

PI3Kδ, IC50: 5.7 nM

98%
Pilaralisib analogue ++

PI3Kα, IC50: 39 nM

++

PI3Kβ, IC50: 36 nM

+++

PI3Kγ, IC50: 23 nM

++

PI3Kδ, IC50: 36 nM

99%+
ZSTK474 +++

PI3Kα, IC50: 16 nM

++

PI3Kβ, IC50: 44 nM

++

PI3Kγ, IC50: 49 nM

+++

PI3Kδ, IC50: 4.6 nM

++

PI3K, IC50: 37 nM

98%
AS-605240 ++

PI3Kα, IC50: 60 nM

+

PI3Kβ, IC50: 270 nM

+++

PI3Kγ, IC50: 8 nM

+

PI3Kδ, IC50: 300 nM

98%
TGX-221 +++

p110β, IC50: 5 nM

++

p110δ, IC50: 0.1 μM

99%+
PF-04691502 ++++

PI3Kα, Ki: 1.8 nM

++++

PI3Kβ, Ki: 2.1 nM

++++

PI3Kγ, Ki: 1.9 nM

++++

PI3Kδ, Ki: 1.6 nM

mTOR 98+%
GDC-0084 ++++

PI3Kα, Ki app: 2 nM

++

PI3Kβ, Ki app: 46 nM

+++

PI3Kγ, Ki app: 10 nM

++++

PI3Kδ, Ki app: 3 nM

mTOR 99%+
Buparlisib ++

p110α, IC50: 52 nM

+

p110β, IC50: 166 nM

+

p110γ, IC50: 262 nM

++

p110δ, IC50: 116 nM

+

Vps34, IC50: 2.4 μM

mTOR 98%
LY294002 +

p110α, IC50: 0.5 μM

+

p110β, IC50: 0.97 μM

+

p110δ, IC50: 0.57 μM

DNA-PK 99%+
AZD 6482 +

PI3Kα, IC50: 870 nM

+++

PI3Kβ, IC50: 10 nM

++

PI3Kδ, IC50: 80 nM

DNA-PK 99%+
Pictilisib ++++

p110α, IC50: 3 nM

++

p110β, IC50: 33 nM

++

p110γ, IC50: 75 nM

++++

p110δ, IC50: 3 nM

mTOR 99%+
PKI-402 ++++

PI3Kα, IC50: 2 nM

+++

PI3Kβ, IC50: 7 nM

+++

PI3Kγ, IC50: 16 nM

+++

PI3Kδ, IC50: 14 nM

mTOR 99+%
Copanlisib ++++

PI3Kα, IC50: 0.5 nM

++++

PI3Kβ, IC50: 3.7 nM

+++

PI3Kγ, IC50: 6.4 nM

++++

PI3Kδ, IC50: 0.7 nM

99%+
Omipalisib ++++

p110α, Ki: 0.019 nM

++++

p110β, Ki: 0.13 nM

++++

p110γ, Ki: 0.06 nM

++++

p110δ, Ki: 0.024 nM

99%+
Izorlisib +++

PI3Kα, IC50: 14 nM

++

PI3Kβ, IC50: 0.12 μM

++

PI3Kγ, IC50: 36 nM

+

PI3Kδ, IC50: 0.50 μM

99%+
AZD8186 ++

PI3Kα, IC50: 35 nM

++++

PI3Kβ, IC50: 4 nM

+++

PI3Kδ, IC50: 12 nM

98+%
KU-0060648 ++++

PI3Kα, IC50: 4 nM

++++

PI3Kβ, IC50: 0.5 nM

+

PI3Kγ, IC50: 0.59 μM

++++

PI3Kδ, IC50: 0.1 nM

DNA-PK 99%
Apitolisib +++

p110α, IC50: 5 nM

++

p110β, IC50: 27 nM

+++

p110γ, IC50: 14 nM

+++

p110δ, IC50: 7 nM

mTOR 98%+
CZC24832 +

PI3Kβ, IC50: 1.1 μM

++

PI3Kγ, IC50: 27 nM

98+%
BGT226 maleate ++++

PI3Kα, IC50: 4 nM

++

PI3Kβ, IC50: 63 nM

++

PI3Kγ, IC50: 38 nM

mTOR 99%+
TG 100713 ++

PI3Kα, IC50: 165 nM

+

PI3Kβ, IC50: 215 nM

++

PI3Kγ, IC50: 50 nM

+++

PI3Kδ, IC50: 24 nM

98%+
PI3K-IN-1 ++

PI3Kα, IC50: 39 nM

++

PI3Kβ, IC50: 113 nM

+++

PI3Kγ, IC50: 9 nM

++

PI3Kδ, IC50: 43 nM

mTOR,DNA-PK 98+%
TG100-115 +

PI3Kα, IC50: 1.3 μM

+

PI3Kβ, IC50: 1.2 μM

++

PI3Kγ, IC50: 83 nM

+

PI3Kδ, IC50: 235 nM

98%
PIK-90 +++

PI3Kα, IC50: 11 nM

+

PI3Kβ, IC50: 350 nM

+++

PI3Kγ, IC50: 18 nM

++

PI3Kδ, IC50: 58 nM

99%+
PIK-294 +

p110β, IC50: 490 nM

++

p110γ, IC50: 160 nM

+++

p110δ, IC50: 10 nM

99%+
Duvelisib ++++

PI3Kβ, Ki: 1564 pM

++

PI3Kγ, Ki: 243 pM

++++

PI3Kδ, Ki: 23 pM

99%+
GDC-0326 ++++

PI3Kα, Ki: 0.2 nM

++

PI3Kβ, Ki: 26.6 nM

+++

PI3Kγ, Ki: 10.2 nM

++++

PI3Kδ, Ki: 4 nM

98%
Quercetin Dihydrate +

PI3Kβ, IC50: 5.4 μM

+

PI3Kγ, IC50: 2.4 μM

+

PI3Kδ, IC50: 3.0 μM

95%
Quercetin +

PI3Kβ, IC50: 5.4 μM

+

PI3Kγ, IC50: 2.4 μM

+

PI3Kδ, IC50: 3.0 μM

Src,Sirtuin,PKC 97%
Leniolisib +

PI3Kα, IC50: 0.244 μM

+

PI3Kβ, IC50: 0.424 μM

+

PI3Kγ, IC50: 2.23 μM

+++

PI3Kδ, IC50: 0.011 μM

DNA-PK 99%+
PIK-108 98%
Eganelisib +++

PI3Kγ, IC50: 16 nM

99%+
CAY10505 98%
IPI-3063 ++++

p110δ, IC50: 2.5 nM

99%
Nemiralisib ++++

PI3Kδ, pKi: 9.9

99%+
PF-4989216 ++++

p110α, IC50: 2 nM

++

p110γ, IC50: 65 nM

++++

p110δ, IC50: 1 nM

99%+
PIK-75 HCl +++

p110α, IC50: 5.8 nM

++

p110γ, IC50: 76 nM

+

p110δ, IC50: 0.51 μM

DNA-PK 99%+
Tenalisib ++

PI3Kγ, IC50: 33.2 nM

++

PI3Kδ, IC50: 24.5 nM

95+%
Acalisib +++

p110δ, IC50: 14 nM

99%+
Umbralisib +++

PI3Kδ, IC50: 22.2 nM

99%+
AMG319 +

PI3Kγ, IC50: 850 nM

+++

PI3Kδ, IC50: 18 nM

99%
IC-87114 +

PI3Kγ, IC50: 29 μM

+

PI3Kδ, IC50: 0.5 μM

99%+
Idelalisib ++

p110γ, IC50: 89 nM

++++

p110δ, IC50: 2.5 nM

98%
PIK-293 +

p110γ, IC50: 10 μM

+

p110δ, IC50: 0.24 μM

99%+
Vps34-PIK-III +

PI3Kδ, IC50: 1.2μM

+++

Vps34, IC50: 0.018μM

99%+
GSK2292767 99+%
Seletalisib +

PI3Kγ, IC50: 282 nM

+++

PI3Kδ, IC50: 12 nM

99%+
P110δ-IN-1 ++++

P110δ, IC50: 0.6 nM

98%
PI3Kδ-IN-5 ++++

PI3Kδ, IC50: 0.9 nM

98%
SRX3207 +

PI3K alpha, IC50: 244 nM

+

PI3K gamma, IC50: 9790 nM

+

PI3K delta, IC50: 388 nM

Syk 98%
Parsaclisib HCl ++++

PI3Kδ, IC50: 1 nM

98%
IHMT-PI3Kδ-372 +++

PI3Kδ, IC50: 14 nM

98%
Trigonelline Akt 99%+
Wortmannin ++++

PI3K, IC50: 3 nM

DNA-PK,MLCK 99%+
Samotolisib DNA-PK 99%+
GNE-317 99%+
Oroxin B PTEN,Akt 99%+
NU 7026 +

PI3K, IC50: 13 μM

DNA-PK 98+%
Deguelin Akt 99%+
Ailanthone CDK,ATM/ATR,Akt 98%
Resibufogenin ROS 98%
KU-57788 +

PI3K, IC50: 5 μM

mTOR,DNA-PK 99%+
Cinobufagine Akt 98%
α-Linolenic acid 97% GC
MTX-211 EGFR 98%
PI3K/mTOR Inhibitor-2 ++++

PI3K, IC50: 3.4 nM

mTOR 99%+
SPP-86 99%+
(E)-Akt inhibitor-IV 98%
Vps34-IN-1 ++

Vps34, IC50: 25 nM

98%
SAR405 ++++

Vps34, IC50: 1.2 nM

98+%
3-Methyladenine +

PI3Kγ, IC50: 60 μM

+

Vps34, IC50: 25 μM

Autophagy 98%
Vps34-IN-4 +++

VPS34, IC50: 15 nM

98%+
Autophinib +++

Vps34, IC50: 19 nM

Autophagy 97%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 NF-κB 其他靶点 纯度
PDTC ammonium 98%
QNZ ++++

NF-κB, IC50: 11 nM

99%+
Sodium 4-Aminosalicylate Dihydrate 98%
Sodium Salicylate 95%
Parthenolide p53 97% HPLC
JSH-23 +

NF-κB, IC50: 7.1 μM

98%
Phenethyl caffeate 98%
Andrographolide 98+%
Curcumin Nrf2,HDAC 98%
SC75741 +++

NF-κB, EC50: 200 nM

99%+
CBL0137 HCl ++

NF-κB, EC50: 0.47 μM

p53 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Resibufogenin 生物活性

靶点
  • PI3K

描述 Necrosis can occur in a highly regulated and genetically controlled manner. Necroptotic susceptibility is probably an intrinsic weakness of cancer. Resibufogenin is a major bioactive compound that belongs to bufadienolide family. It is isolated from toad venom. Resibufogenin decreased the cell viability dose-dependently in HCT116 cells. The clonogenic cell survival assay showed that resibufogenin significantly reduced the number of cell clones as compared to the control group, provided further evidence that resibufogenin is an effective antineoplastic agent through inhibiting cell proliferation. Extensive organelle and cell swelling, cytoplasmic vacuolation were observed in resibufogenin-treated SW480 and HCT116. Intracellular ROS (reactive oxygen species) level was also increased in a dose-dependent manner in resibufogenin treated cells. After administration (i.p.) of resibufogenin at 5 and 10 mg/kg/day in mice for 21 days, the weight of tumor in situ were significantly reduced by 27 and 41%, respectively. Vernier caliper measurement showed that resibufogenin decreased the tumor volume in a dose-dependent manner. The weight loss caused by tumor growth was significantly ameliorated by high dose of resibufogenin. These results provide strong evidence that resibufogenin suppresses tumor growth of CRC (colorectal cancer) and ameliorates the weight loss in tumor-bearing mice. Remarkable increase in levels of PYGL, GLUD1 and GLUL as well as increase of RIP3 in resibufogenin-treated mice compared with the control group suggests that resibufogenin inhibits tumor growth through inducing RIP3-mediated activation of PYGL, GLUD1 and GLUL to induce necroptosis in CRC cells[3].

Resibufogenin 参考文献

[1]Ning J, Yu ZL, et al. Characterization of phase I metabolism of resibufogenin and evaluation of the metabolic effects on its antitumor activity and toxicity. Drug Metab Dispos. 2015 Mar;43(3):299-308.

[2]Zhu ZT, Deng S, et al. Isolation and identification of phase I metabolites of resibufogenin in rats. Xenobiotica. 2013 May;43(5):479-85.

[3]Han Q, Ma Y, Wang H, et al. Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis. J Transl Med. 2018;16(1):201

Resibufogenin 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.60mL

0.52mL

0.26mL

13.00mL

2.60mL

1.30mL

26.01mL

5.20mL

2.60mL

Resibufogenin 技术信息

CAS号465-39-4
分子式C24H32O4
分子量 384.509
别名 蟾力苏 ;Bufogenin;Recibufogenin;Bufotenine;RBG;Respigon;NSC 90783
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,2-8°C

溶解度

DMSO: 105 mg/mL(273.08 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。